High doses of statins may reduce the lipid content in severe injury

Original title: Changes in Plaque Lipid Content After Short-Term Intensive Versus Standard Statin Therapy. The YELLOW Trial (Reduction in Yellow Plaque by Aggressive Lipid-Lowering Therapy). Reference: Annapoorna S. Kini et al. J Am Coll Cardiol 2013;62:21–9.

Multiple studies have shown the benefits of statins in reducing all events, stabilize plaques and improve endothelial function. Coronary intravascular ultrasound (IVUS) reduction in nonsignificant atherosclerotic plaque volume has been objectivized after administration of statins, however severe plaque effect is unknown.

The aim of this study was to determine the impact of intensive lipid lowering over the lipid content and the physiology of severe plaques using spectroscopy (NIRS = near-infrared spectroscopy), fractional flow reserve (FFR) and IVUS. 87 patients were randomized to standard versus intensive lipid-lowering therapy (Rosuvastatin 40 mg) which were treated in a programmed culprit injury but also having other stenosis lesions with a diameter of> 70% and measuring FFR ≤ 0.8. None of the non-culprit injuries received angioplasty at the time of randomization. After 6 to 8 weeks these non-culprit injuries were evaluated again using angiography, FFR, IVUS and NIRS before any angioplasty. At the end of follow-up, cholesterol values

More articles by this author

Morpheus Global Registry: Safety and efficacy of the long tapered BioMime™ Morph stent in complex coronary lesions

Percutaneous coronary intervention in long coronary lesions continues to represent a technical and clinical challenge, in which the use of conventional cylindrical stents may...

Hybrid Coronary Revascularization versus Conventional Bypass Surgery in Left Main Coronary Artery Disease

Significant left main coronary artery (LMCA) disease continues to represent a therapeutic challenge, particularly in patients with complex multivessel disease and high SYNTAX scores,...

Comparison of strategies: NMA of IVUS, OCT, or angiography in complex lesions

Percutaneous coronary intervention (PCI) in complex lesions continues to represent a technical challenge in contemporary interventional cardiology. Angiography, although it remains the most widely...

Dynamic Coronary Roadmap: does it really help reduce contrast use?

Contrast-induced nephropathy remains a relevant complication of percutaneous coronary interventions (PCI), particularly in patients with multiple comorbidities and complex coronary anatomies. Dynamic Coronary Roadmap...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long-Term Predictors of Valve Deterioration After TAVI

Transcatheter aortic valve implantation (TAVI) has become an innovative technology for the treatment of patients with severe aortic valve stenosis. Initially implemented in elderly...

Coronary access after TAVI with fourth- and fifth-generation Evolut valves: the EPROMPT-CA study

The expansion of transcatheter aortic valve implantation (TAVI) toward younger and lower-risk patients has increased the relevance of post-procedural coronary access. In this context,...

Morpheus Global Registry: Safety and efficacy of the long tapered BioMime™ Morph stent in complex coronary lesions

Percutaneous coronary intervention in long coronary lesions continues to represent a technical and clinical challenge, in which the use of conventional cylindrical stents may...